Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
ACNT Ascent Industries Co
FATH Fathom Digital Manufacturing Corp
PAYX Paychex Inc
WAVD Wavedancer Inc
RNXT RenovoRx Inc
GBNY Generations Bancorp NY Inc
POL Polished.Com Inc
MDGS Medigus Ltd
GTH Genetron Holdings Ltd
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Price
Delayed
$11.07
Day's Change
-0.39 (-3.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.48
Day's Low
11.07
Volume
(Light)

Today's volume of 1,384 shares is on pace to be much lighter than AGLE's 10-day average volume of 29,404 shares.

1,384

Display:

Providers:

UpdateCancel
All providers
September 14, 2023
Aeglea BioTherapeutics to Participate in Upcoming September Conference

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will...(PR Newswire)

September 07, 2023
Aeglea BioTherapeutics Announces Reverse Stock Split

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a...(PR Newswire)

September 05, 2023
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Scott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer Heidy Abreu King-Jones, former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer & Corporate Secretary (PR Newswire)

August 11, 2023
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including a4b7 and TL1A programs (PR Newswire)

July 27, 2023
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is...(PR Newswire)

July 25, 2023
Aeglea BioTherapeutics started at buy with 90-cent stock price target at Stifel

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.